This was truly a low point in LymeLand where a 'perfect storm' of enablers & phoney patients used websites, newsletters--the whole nine manipulative yards--to push an eye popping illegal scam by a 'doctor' who didn't even have a medical license. It had been revoked in 1990 because of a serious criminal conviction.
He had spent 8 years in federal prison for using the same scam substance DNP in weight loss clinics, and he came right out to use it on cancer patients and Lyme patients. Even though factual information--including legal documentation--was made readily available to patients on popular newsgroups--it was deleted and censored, sometimes within minutes of the posts. Sci.med.diseases.lyme was then used to record as much as possible.
There is updated information here: http://www.quackwatch.org/01QuackeryRel ... /icht.html
I'll post some tidbits because it is a good history lesson about how LymeLand deals with medical fraud: it not only embraces it but gives it a home. And, you can pretty much get away with murder, literally. In fact, after this guy caused the death of a patient, an M.D., you can still read about those who support him.
For sure, if you don't have a medical license and were convicted on serious charges and imprisioned you'll find that doesn't seem to bother your enablers.
Do I expect people on the whole to learn from history? Well, the quacks and charlatans know they can get away with as much as the people let them. And Bachnysky is a case study in how to do just that. Although it was before his type were invited to symposia, had books written about them, and had their butts kissed by hangers on who could make even more money promoting the scams or adding to them.
So can this kind of stuff happen again? Yes, with bells on.
Let's start at the end:
Just recently, Bachnysky was found guilty on SEC (Security and Exchange) charges. That was what brought him down:
http://miami.fbi.gov/dojpressrel/pressr ... 062008.htm
FOR IMMEDIATE RELEASE
R. Alexander Acosta, United States Attorney for the Southern District
of Florida, and Jonathan I. Solomon, Special Agent in Charge, Federal
Bureau of Investigation, announced that on Monday, May 5, 2008, a jury
convicted defendant Nicholas Bachynsky of one count of conspiracy,
three counts of wire fraud, and one count of securities fraud.
Bachynsky, who is 65 years-old, faces a 5-year maximum term of
imprisonment per count for the conspiracy and wire fraud convictions
and a 10-year maximum term of imprisonment for the securities fraud
conviction. The jury also returned a supplemental verdict forfeiting
Bachynsky’s interest in $450,000 in United States currency and two
Swiss bank accounts.
Bachynsky’s sentencing is set for September 5, 2008, at 9:00am before
U.S. District Court Judge Adalberto Jordan.
Bachynsky’s three co-defendants in the case – Arthur Scheinert,
Laurence Dean, and Richard Anders – have all pled guilty. Both
Scheinert and Dean already have been sentenced to 5-year terms of
imprisonment. Anders is pending sentencing on May 16, 2008, before
As was set forth during the six and a half week trial, the scheme that
resulted in Bachynsky’s conviction arose out of the marketing of stock
and notes for a start-up company known as Helvetia Pharmaceuticals,
Inc. Helvetia was launched in early 2001 to administer and develop a
cancer treatment in Europe known as intracellular hyperthermia
therapy. Helvetia’s solicitation of investors was centered around a
series of sales materials that contained a succession of significant
representations. Bachynsky was the primary author of the false
representations contained in the Helvetia sales materials.
During the trial the government called witnesses and introduced
exhibits that showed that the sales materials falsified the results of
a series of unsuccessful laboratory and clinical trials, claiming that
the trials had shown the therapy to be successful. The sales materials
also falsely claimed that Helvetia possessed exclusive rights to the
intercellular hyperthermia therapy. However, several years earlier
Bachynsky had sold the rights to therapy to a former business
associate. The sales materials further falsely claimed that the
treatment was non-toxic, when in fact the treatment was based upon a
substance that was not approved for human consumption by the federal
Food and Drug Administration and was used commercially in pesticides
and wood preservatives. The sales materials also covered up
Bachynsky’s true role in the company and failed to disclose both his
criminal history and adverse regulatory history.
Between early 2001 and August 2002, Helvetia raised close to $6
million from investors. Most investors lost their entire investment.
Substantial portions of investor funds were misappropriated by
Helvetia insiders for their own personal use.
Mr. Acosta commended the investigative efforts of the Federal Bureau
of Investigation. Mr. Acosta also expressed appreciation for the
cooperative efforts of the Southeast Regional Office of the Securities
and Exchange Commission. Bachynsky’s conviction followed more than
three years of extensive pre-trial litigation in this case. From the
summer of 2004 until his passing in late September 2007, the case was
prosecuted by Assistant United States Attorney Hugo L. Black, III.
Bachynsky was tried by Assistant United States Attorneys Michael Davis
and Mark Dispoto. AUSAs Davis and Dispoto were assisted by certified
legal intern Allison Soares of St. Thomas University School of Law,
and paralegal specialist Maureen Booker of the U.S. Attorney’s
A copy of this press release may be found on the website of the United
States Attorney's Office for the Southern District of Florida at
http://www.usdoj.gov/usao/fls. Related court documents and information
may be found on the website of the District Court for the Southern
District of Florida at http://www.flsd.uscourts.gov or on